Press Releases and Events
PRESS RELEASES
Press Release | November 15, 2024
Press Release | November 12, 2024
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
READ MORE
Press Release | November 12, 2024
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
READ MORE
Press Release | November 11, 2024
Crinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | October 10, 2024
Crinetics Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | October 8, 2024
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
READ MORE
Press Release | October 8, 2024
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
READ MORE
Press Release | September 26, 2024
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
READ MORE
Press Release | September 10, 2024
Crinetics Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | August 29, 2024
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
